{'fraction_non_alphanumeric': 0.07742998352553541, 'fraction_numerical': 0.011532125205930808, 'mean_word_length': 5.268041237113402, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[D-Met2]-FMRFamide (DMFa): production of naloxone-sensitive antinociception in mouse tail-flick test.

Considerable data support the hypothesis that mammalian FMRFamide (Phe-Met-Arg-Phe-NH2) or mammalian FMRFamide-related peptides (FaRPs) function as endogenous antiopiates (for review see Raffa, 1988). We report here that central administration (i.c.v.) of a FaRP with D-amino acid substitution in the second position, i.e. [D-Met2]-FMRFamide (DMFa), produces dose-related, naloxone-reversible antinociception in the mouse tail-flick test. Hence, this modification appears to confer agonist-like activity.